BACKGROUND: To determine the cardiotoxicity of paclitaxel (T) plus doxorubicin (A) combination therapy in women with advanced breast cancer. To define a dose range of A for use in AT. PATIENTS AND METHODS: The effect of cumulative A dose on risk of congestive heart failure (CHF) and alterations of myocardial contractility (left ventricular ejection fraction [LVEF] decrease > or = 20% or to <50%) was estimated from pooled data from 10 trials of AT. RESULTS: Thirty-one of 657 patients (4.7%) developed CHF at a median of 6.6 months (range 0.3-24.6) after initiation of AT. CHF was stabilized in 29 patients at a median of 17.3 months after diagnosis (range 4.1-31.2 months). The risk of developing CHF was < or = 5% at a total A dose < or = 380 mg/m2. In patients who received a total A dose > 440 mg/m2, the incidence of CHF was >25% but similar to that of A monotherapy. The risk of CHF was similar in women receiving AT or A monotherapy at a dose < or = 380 mg/m2 (2%-3%). LVEF progressively decreased in patients who received AT, especially at a cumulative A dose > 380 mg/m2. LVEF decreases were more frequent in patients who later developed CHF, but the majority of CHF patients did not experience LVEF alterations prior to symptoms. LVEF recovered after discontinuation of A in 25 of 67 women who developed LVEF < 50%. CONCLUSION: The reported cardiac effects are consistent with anthracycline-related cardiotoxicity. AT is associated with a cardiac risk similar to that of A monotherapy up to a cumulative A dose of 340-380 mg/m2.
BACKGROUND: To determine the cardiotoxicity of paclitaxel (T) plus doxorubicin (A) combination therapy in women with advanced breast cancer. To define a dose range of A for use in AT. PATIENTS AND METHODS: The effect of cumulative A dose on risk of congestive heart failure (CHF) and alterations of myocardial contractility (left ventricular ejection fraction [LVEF] decrease > or = 20% or to <50%) was estimated from pooled data from 10 trials of AT. RESULTS: Thirty-one of 657 patients (4.7%) developed CHF at a median of 6.6 months (range 0.3-24.6) after initiation of AT. CHF was stabilized in 29 patients at a median of 17.3 months after diagnosis (range 4.1-31.2 months). The risk of developing CHF was < or = 5% at a total A dose < or = 380 mg/m2. In patients who received a total A dose > 440 mg/m2, the incidence of CHF was >25% but similar to that of A monotherapy. The risk of CHF was similar in women receiving AT or A monotherapy at a dose < or = 380 mg/m2 (2%-3%). LVEF progressively decreased in patients who received AT, especially at a cumulative A dose > 380 mg/m2. LVEF decreases were more frequent in patients who later developed CHF, but the majority of CHFpatients did not experience LVEF alterations prior to symptoms. LVEF recovered after discontinuation of A in 25 of 67 women who developed LVEF < 50%. CONCLUSION: The reported cardiac effects are consistent with anthracycline-related cardiotoxicity. AT is associated with a cardiac risk similar to that of A monotherapy up to a cumulative A dose of 340-380 mg/m2.
Authors: Ron Shapiro; Daphna Barsuk; Lior Segev; Shani Shimon-Paluch; Haim Berkenstadt; Douglas B Zippel; Moshe Z Papa Journal: Ann R Coll Surg Engl Date: 2010-11-18 Impact factor: 1.891
Authors: P Schütt; K Zimmermann; C Derks; P Ebeling; A Welt; M Poser; J Hense; K Metz; J Anhuf; M Sandmann; M Neise; T Moritz; M Stuschke; N Niederle; S Seeber; Mohammad R Nowrousian Journal: J Cancer Res Clin Oncol Date: 2008-08-29 Impact factor: 4.553
Authors: Nicolas Magné; Rémy Largillier; Pierre-Yves Marcy; Jacques Magné; Moïse Namer Journal: Support Care Cancer Date: 2005-03-30 Impact factor: 3.603
Authors: Arlene O Siefker-Radtke; Matthew T Campbell; Mark F Munsell; Deborah R Harris; Robert L Carolla; Lance C Pagliaro Journal: Urology Date: 2015-12-23 Impact factor: 2.649
Authors: City C Hsieh; Lisa K Sprod; David S Hydock; Susan D Carter; Reid Hayward; Carole M Schneider Journal: Oncol Nurs Forum Date: 2008-11 Impact factor: 2.172